The Green Cross Corporation

Medigenebio Corporation

Daewoong Co., Ltd.

Haplnscience Inc.

Yo Kyung Chung

Yong-Chul Kim

Jinwook Seo

Thong-Gyu Jin

Sang Hoon Paik

Yong Woon Choi

Yoo Chang Park

Jong Mun Son

Seung Kook Park

Sang Kil Lee

Dae Kyong Kim

Jae Young Chang

Sun Hee Kim

Min Suk Lee

A composition comprising recombinant iduronate-2-sulfatase (IDS) and a method for producing a purified recombinant IDS are provided. The glycosylation pattern and formylglycine content of the IDS composition are different from those of ELAPRASE&#xae; and have superior pharmaceutical efficacy and are safer than the conventional agent and thus can be effectively used for the therapy of Hunter Syndrome.

Composition and formulation comprising recombinant human iduronate-2-sulfatase and preparation method thereof

A composition comprising recombinant iduronate-2-sulfatase (IDS) and a method for producing a purified recombinant IDS are provided. The glycosylation pattern and formylglycine content of the IDS composition are different from those of ELAPRASE&#xae; and have superior pharmaceutical efficacy and are safer than the conventional agent and thus can be effectively used for the therapy of Hunter syndrome.

Disclosed are a composition comprising recombinant iduronate-2-sulfatase (IDS) and a method for treating Hunter syndrome. The glycosylation pattern and formylglycine content of the IDS composition are different from those of ELAPRASE&#xae; and have superior pharmaceutical efficacy and are safer than the conventional agent and thus can be effectively used for the therapy of Hunter syndrome.

Disclosed is a composition comprising recombinant iduronate-2-sulfatase (IDS). The glycosylation pattern and formylglycine content of the IDS composition are different from those of Elaprase and have superior pharmaceutical efficacy and are safer than the conventional agent and thus can be effectively used for the therapy of Hunter syndrome.

Disclosed herein is a stable liquid formulation comprising human growth hormone; L-lysine, L-arginine or polyethylene glycol 300; and poly(oxyethylene) poly(oxypropylene) copolymer, polyethylene glycol-15 polyoxystearate or polyethylene glycol-35 castor oil.

Stable liquid formulation of human growth hormone

Growing community of inventors

Yongin-si, South Korea

Yo Kyung Chung